01:00 PM EDT, 03/19/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) on Tuesday said it received the US Food and Drug Administration's approval to expand the indication of Iclusig to include the treatment of adult patients who are newly diagnosed with a sub type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia.

The company's supplemental new drug application was approved under the FDA's accelerated approval pathway and the company may be required to verify the medicine's benefit in confirmatory trials to maintain the regulator's decision.

Price: 14.43, Change: -0.13, Percent Change: -0.89